Esperion Therapeutics, Inc. (ESPR) earnings
ESPR earnings moved a median of 0.00% by the close. Quarterly and annual ESPR reports and results, each read against the price at its own news timestamp. Back to the ESPR overview →
27 measured ESPR earnings events.
Where these ESPR earnings landedvs 26 measured ESPR earnings reactions
| Middle 50% of ESPR earnings reactions | -2.83% to +6.04% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 26 |
Point-in-time · zero look-ahead
Half of the 26 ESPR earnings events with a measured close landed between -2.83% and +6.04%; 42% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Esperion Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.16% | -0.32% | |
| Esperion to Report First Quarter 2026 Financial Results on May 7 | Press release | -0.51% | -3.54% | |
| Form 10-K Esperion Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.12% | -3.36% | |
| Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | -5.80% | -9.42% | |
| Form 10-Q Esperion Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.40% | +6.40% | |
| Esperion to Report Third Quarter 2025 Financial Results on November 6 | Press release | +0.00% | -2.19% | |
| Form 10-Q Esperion Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -1.03% | +6.70% | |
| Form NT 10-Q Esperion Therapeutics, For: Jun 30 | SEC filing · Form NT | -1.07% | — | |
| Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | -0.31% | -0.61% | |
| Esperion to Report Second Quarter 2025 Financial Results on August 5 | Press release | +1.32% | +7.02% | |
| Form 10-Q Esperion Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +1.46% | |
| Esperion Reports First Quarter 2025 Financial Results | Press release | +3.96% | -3.42% | |
| Esperion to Report First Quarter 2025 Financial Results on May 6 | Press release | +5.98% | -3.27% | |
| Form 10-K Esperion Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.64% | +7.64% | |
| Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update | Press release | +4.48% | +4.97% | |
| Form 10-Q Esperion Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +1.20% | +9.09% | |
| Esperion to Report Third Quarter 2024 Financial Results on November 7 | Press release | +0.00% | +0.00% | |
| Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update | Press release | +2.15% | -1.07% | |
| Form 10-Q Esperion Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -1.88% | -3.23% | |
| Esperion to Report Second Quarter 2024 Financial Results on August 12 | Press release | -1.29% | +4.29% | |
| Esperion Reports First Quarter 2024 Financial Results | Press release | +5.27% | +0.00% | |
| Form 10-Q Esperion Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +5.27% | +0.00% | |
| Esperion to Report First Quarter 2024 Financial Results on May 7 | Press release | +2.59% | +8.29% | |
| Form 10-K Esperion Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -4.53% | +9.43% | |
| Esperion Reports Third Quarter 2023 Financial Results | Press release | +0.00% | -2.83% | |
| Form 10-Q Esperion Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -2.83% | |
| Esperion to Report Third Quarter 2023 Financial Results on November 7 | Press release | +5.07% | +2.38% |
Keep exploring
More ESPR: analyst actions → · SEC filings → · ESPR overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Blueprint Medicines Corporation (BPMC) | 401 | -0.03% | 46% |
| EDGE THERAPEUTICS (EDGE) | 401 | -0.05% | 41% |
| Novavax, Inc. (NVAX) | 400 | 0.00% | 48% |
| AMEDICA CORP COMMON STOCK (AMDA) | 397 | -1.09% | 31% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.